SCHEMBL7433871

SCHEMBL7433871

O=[C]C1CCCCC(=O)N1

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.34
FKBP5 Q13451 1/20 0.34
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
KMT2A Q03164 1/20 0.31
OR51E2 Q9H255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7428318 0.98 KMT2A (0.34) CRBNFKBP5CA1CA2CA4
SCHEMBL7433746 0.98 KMT2A (0.34) CRBNFKBP5CA1CA2CA4
SCHEMBL7430825 0.98 KMT2A (0.34) CRBNFKBP5CA1CA2CA4
SCHEMBL6271848 0.93
SCHEMBL2267145 0.84
SCHEMBL21473 0.84
SCHEMBL37624 0.84
SCHEMBL28517253 0.74
SCHEMBL1272610 0.71 CRBN (0.36) CRBNFKBP5CA1CA2CA4
SCHEMBL9732480 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-09-13 US disclosed
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-17 US disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
US-9708320-B2 β-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-07-18 US disclosed
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-28 US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 EP disclosed
EP-0462884-B1 TRH DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR ET COMPAGNIE (FR) 1993-06-16 EP disclosed
US-5190923-A For treatment of neurological disorders such as cognitive disorders ADIR ET COMPAGNIE (FR) 1993-03-02 US disclosed
EP-0462884-A1 TRH derivatives, their preparations and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, MRPL21, FNTB CRBN 459/4885FKBP5 4259/4885CA1 1822/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB CRBN 539/4885FKBP5 4457/4885CA1 2224/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same FN1, FNTB, CPN1 CRBN 100/4885FKBP5 4261/4885CA1 3514/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 CRBN 100/4885FKBP5 4261/4885CA1 3514/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 CRBN 82/4885FKBP5 4027/4885CA1 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.